AI Engines For more Details: Perplexity Kagi Labs You
Hypertension (High Blood Pressure): Esmolol hydrochloride is often used in the acute management of hypertension, especially in situations where blood pressure needs to be rapidly controlled, such as during surgery, hypertensive emergencies, or acute coronary syndromes. Its rapid onset of action and short duration of effect make it particularly useful in these settings.
Supraventricular Tachycardia (SVT): Esmolol hydrochloride is effective in the treatment of supraventricular tachycardia, a condition characterized by abnormally fast heart rhythms originating above the ventricles. By blocking beta-adrenergic receptors in the heart, esmolol slows down the heart rate and helps restore normal rhythm.
Atrial Fibrillation and Atrial Flutter: Esmolol hydrochloride may be used to control rapid heart rates associated with atrial fibrillation or atrial flutter, particularly when other measures such as electrical cardioversion or pharmacological rhythm control agents are contraindicated or ineffective.
Perioperative Tachycardia: Esmolol hydrochloride is commonly administered during surgery to attenuate tachycardia (rapid heart rate) and hypertension caused by factors such as anesthesia, surgical stimulation, or endotracheal intubation. It helps maintain hemodynamic stability during the perioperative period.
Acute Myocardial Infarction (Heart Attack): Esmolol hydrochloride may be used as part of the treatment strategy for acute myocardial infarction to reduce myocardial oxygen demand and alleviate symptoms such as chest pain and ischemia. However, its use in this context must be carefully considered, especially in patients with compromised cardiac function.
Heart Failure: In certain cases of acute decompensated heart failure with elevated heart rates, esmolol hydrochloride may be used cautiously to reduce heart rate and myocardial oxygen consumption. However, its use in heart failure requires careful monitoring due to the potential risk of worsening cardiac function.
Arrhythmias: Esmolol hydrochloride may also be used to manage various types of cardiac arrhythmias, including ventricular tachycardia or fibrillation, although its efficacy in these conditions may vary, and other antiarrhythmic agents may be preferred depending on the specific situation.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 0.1 | 0.3 | -2 |
| Allergy to milk products | 0.3 | 0.3 | 0 |
| Alzheimer's disease | 0.3 | 0.9 | -2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.4 | 0.4 | |
| Ankylosing spondylitis | 0.6 | 0.6 | 0 |
| Anorexia Nervosa | 0.6 | -0.6 | |
| Asthma | 0.6 | 0.3 | 1 |
| Atherosclerosis | 0.3 | 0.3 | 0 |
| Atrial fibrillation | 0.6 | 0.3 | 1 |
| Autism | 0.3 | 0.7 | -1.33 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Bipolar Disorder | 0.3 | 0.3 | |
| Brain Trauma | 0.3 | -0.3 | |
| Cancer (General) | 0.4 | -0.4 | |
| Carcinoma | 0.3 | 0.3 | 0 |
| Celiac Disease | 0.3 | 0.6 | -1 |
| Cerebral Palsy | 0.3 | 0.3 | 0 |
| Chronic Fatigue Syndrome | 0.3 | 0.3 | 0 |
| Chronic Kidney Disease | 0.6 | 0.3 | 1 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | -0.3 | |
| Chronic Urticaria (Hives) | 0.1 | -0.1 | |
| Cognitive Function | 0.3 | 0.3 | |
| Colorectal Cancer | 0.3 | 0.3 | 0 |
| Constipation | 0.6 | 0.6 | |
| Coronary artery disease | 0.3 | -0.3 | |
| COVID-19 | 0.3 | 0.6 | -1 |
| Crohn's Disease | 0.3 | 0.7 | -1.33 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.1 | 0.3 | -2 |
| Depression | 1 | 0.6 | 0.67 |
| Eczema | 0.1 | -0.1 | |
| Endometriosis | 0.3 | 0.3 | 0 |
| Epilepsy | 0.3 | 0.3 | 0 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.3 | -0.3 | |
| Functional constipation / chronic idiopathic constipation | 0.6 | 0.6 | 0 |
| gallstone disease (gsd) | 0.1 | 0.1 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.3 | -2 |
| Generalized anxiety disorder | 0.3 | 0.3 | 0 |
| Gout | 0.6 | 0.6 | |
| Graves' disease | 0.3 | 0.3 | 0 |
| Gulf War Syndrome | 0.1 | -0.1 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.3 | 0.6 | -1 |
| Heart Failure | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| hyperglycemia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.6 | 0.4 | 0.5 |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.3 | 0 | 0 |
| Inflammatory Bowel Disease | 0.3 | 0.6 | -1 |
| Insomnia | 0.3 | 0.6 | -1 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 0.6 | 0.6 | 0 |
| ischemic stroke | 0.3 | 0.3 | 0 |
| Liver Cirrhosis | 0.3 | 0.3 | 0 |
| Long COVID | 0.9 | 0.6 | 0.5 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.3 | -0.3 | |
| Metabolic Syndrome | 0.6 | 0.3 | 1 |
| Mood Disorders | 1 | 0.6 | 0.67 |
| Multiple Sclerosis | 0.4 | -0.4 | |
| neuropathic pain | 0.6 | -0.6 | |
| Neuropathy (all types) | 0.3 | -0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 0.6 | 0 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 0.9 | 0.7 | 0.29 |
| obsessive-compulsive disorder | 0.6 | 0.3 | 1 |
| Osteoarthritis | 0.3 | 0.3 | 0 |
| Osteoporosis | 0.3 | 0.3 | 0 |
| pancreatic cancer | 0.3 | -0.3 | |
| Parkinson's Disease | 0.3 | 0.6 | -1 |
| Polycystic ovary syndrome | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 0.3 | 0.3 | |
| Psoriasis | 0.1 | 0.3 | -2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.3 | 1 |
| Schizophrenia | 0.6 | 0.6 | 0 |
| scoliosis | 0 | 0 | |
| Sjögren syndrome | 0.3 | -0.3 | |
| Sleep Apnea | 0.3 | 0.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.3 | 0 |
| Systemic Lupus Erythematosus | 0.3 | 0.3 | 0 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 0.3 | 0.6 | -1 |
| Type 2 Diabetes | 0.6 | 0.4 | 0.5 |
| Ulcerative colitis | 0.6 | 0.3 | 1 |
| Unhealthy Ageing | 0.3 | 0.3 | |
| Vitiligo | 0.6 | 0.6 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
